^
Association details:
| Biomarker: | ATM deletion |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | peposertib (M3814) (DNA PK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer
Published date:
11/22/2023
Excerpt:
We observed a marked increase in sensitivity to the DNA-PK inhibitor nedisertib in ATM-deleted compared to WT ATM bladder cancer cells (Fig. 3M and fig. S8I). Together, these data suggest that ATM deletion is sufficient to increase sensitivity to multiple DNA repair–directed agents across bladder cancer preclinical models.
DOI:
10.1126/sciadv.adg2263
